Evaluation of the Hematological and Serum Biochemistry Parameters in the Pre-Symptomatic and Symptomatic Stages of ALS Disease to Support Early Diagnosis and Prognosis

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease. Since there are no pathognomonic tests for ALS prognoses; clinical diagnoses of the disease take time and are usually difficult. Prognostic biomarkers are urgently needed for rapid and effective ALS prognoses. Male albino rats were divided into ten groups based on age: 0 (40–45 days old), A (70–75 days old), B (90–95 days old), C (110–115 days old), and D (130–135 days old). Each group was divided into two subgroups according to its mutation status: wild type (SOD1WT) or mutated (SOD1G93A). Serum biochemistry and hematological parameters were measured in 90 rats to evaluate possible biomarkers for faster ALS diagnoses and prognoses. Weight loss, cholesterol, creatinine, glucose, total bilirubin (TBIL), blood urine nitrogen (BUN), c-peptide, glucagon, PYY, white blood cell (WBC), lymphocyte (LYM), monocyte (MID), granulocyte (GRAN), red cell distribution width with standard deviation (RDW-SD), red cell distribution width with the coefficient of variation (RDW-CV), platelet (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and procalcitonin (PCT) levels were changed in the SOD1G93A rats compared to the SOD1WT rats independently from aging. For the first time in the literature, we showed promising hematological and serum biochemistry parameters in the pre-symptomatic and symptomatic stages of ALS by eliminating the effects of aging. Our results can be used for early diagnoses and prognoses of ALS, improving the quality of life and survival time of ALS patients.

[1]  P. Reynier,et al.  Metabolic Profile and Pathological Alterations in the Muscle of Patients with Early-Stage Amyotrophic Lateral Sclerosis , 2022, Biomedicines.

[2]  Peng Wu,et al.  Comparative Assessment of Blood Metal/metalloid levels, Clinical Heterogeneity, and Disease Severity in Amyotrophic Lateral Sclerosis Patients. , 2022, Neurotoxicology.

[3]  Y. Aksoy,et al.  Protective Effects of Antioxidant Chlorophyllin in Chemically Induced Breast Cancer Model In vivo , 2021, Biological Trace Element Research.

[4]  E. Scilingo,et al.  Using blood data for the differential diagnosis and prognosis of motor neuron diseases: a new dataset for machine learning applications , 2021, Scientific Reports.

[5]  M. Karajibani,et al.  The Relationship Between Malnutrition and Liver Enzymes in Hospitalized Children in Zahedan: A Case-control Study , 2021, Zahedan Journal of Research in Medical Sciences.

[6]  Qi-Jie Zhang,et al.  Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis , 2021, Annals of clinical and translational neurology.

[7]  S. Sardi,et al.  Sterol auto-oxidation adversely affects human motor neuron viability and is a neuropathological feature of amyotrophic lateral sclerosis , 2021, Scientific reports.

[8]  K. Borges,et al.  CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target? , 2021, Cell & Bioscience.

[9]  L. H. van den Berg,et al.  Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[10]  Y. Pawitan,et al.  Blood biomarkers and prognosis of amyotrophic lateral sclerosis , 2020, European journal of neurology.

[11]  N. N. Ulusu,et al.  Evaluation of the biocompatibility of the GSH-coated Ag2S quantum dots in vitro: a perfect example for the non-toxic optical probes , 2020, Molecular Biology Reports.

[12]  C. Tiribelli,et al.  Bilirubin and inflammation in neurodegenerative and other neurological diseases , 2020 .

[13]  T. Woodruff,et al.  The Peripheral Immune System and Amyotrophic Lateral Sclerosis , 2020, Frontiers in Neurology.

[14]  N. N. Ulusu,et al.  Importance of the serum biochemical parameters as potential biomarkers for rapid diagnosis and evaluating preclinical stage of ALS. , 2020, Medical hypotheses.

[15]  N. N. Ulusu,et al.  Dataset of the analyzing trace elements and minerals via ICP-MS: Method validation for the mammalian tissue and serum samples , 2020, Data in Brief.

[16]  N. N. Ulusu,et al.  Comment on the: Molecular mechanism of CAT and SOD activity change under MPA-CdTe quantum dots induced oxidative stress in the mouse primary hepatocytes (Spectrochim Acta A Mol Biomol Spectrosc. 2019 Sep 5; 220:117104). , 2019, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[17]  N. N. Ulusu,et al.  Effects of butylparaben on antioxidant enzyme activities and histopathological changes in rat tissues , 2019, Arhiv za higijenu rada i toksikologiju.

[18]  Ehsan Sarayloo,et al.  Rosiglitazone-induced changes in the oxidative stress metabolism and fatty acid composition in relation with trace element status in the primary adipocytes , 2019, Journal of medical biochemistry.

[19]  Stanley E. Lazic,et al.  Determining organ weight toxicity with Bayesian causal models: Improving on the analysis of relative organ weights , 2019, bioRxiv.

[20]  F. Fang,et al.  Epidemiology of amyotrophic lateral sclerosis: an update of recent literature , 2019, Current opinion in neurology.

[21]  J. González de Aguilar Lipid Biomarkers for Amyotrophic Lateral Sclerosis , 2019, Front. Neurol..

[22]  A. Musarò,et al.  Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options , 2019, Scientific Reports.

[23]  A. Chiò,et al.  Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort , 2019, Journal of Neurology Neurosurgery & Psychiatry.

[24]  N. N. Ulusu,et al.  Impact of the Di(2-Ethylhexyl) Phthalate Administration on Trace Element and Mineral Levels in Relation of Kidney and Liver Damage in Rats , 2018, Biological Trace Element Research.

[25]  K. Torén,et al.  Risk factors in Swedish young men for amyotrophic lateral sclerosis in adulthood , 2017, Journal of Neurology.

[26]  H. Shang,et al.  Blood hemoglobin A1c levels and amyotrophic lateral sclerosis survival , 2017, Molecular Neurodegeneration.

[27]  P. Shaw,et al.  The role of mitochondria in amyotrophic lateral sclerosis , 2017, Neuroscience Letters.

[28]  R. Mariotti,et al.  ALS Pathogenesis and Therapeutic Approaches: The Role of Mesenchymal Stem Cells and Extracellular Vesicles , 2017, Front. Cell. Neurosci..

[29]  Margaret Warner,et al.  Defective cholesterol metabolism in amyotrophic lateral sclerosis[S] , 2016, Journal of Lipid Research.

[30]  Shishira S. Bharadwaj,et al.  Malnutrition: laboratory markers vs nutritional assessment , 2016, Gastroenterology report.

[31]  T. Woodruff,et al.  Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis , 2015, Journal of the Neurological Sciences.

[32]  F. Piehl,et al.  Risk factors for amyotrophic lateral sclerosis , 2015, Clinical epidemiology.

[33]  A. Chiò,et al.  Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. , 2014, JAMA neurology.

[34]  A. Hattersley,et al.  The clinical utility of C-peptide measurement in the care of patients with diabetes , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[35]  L. Nguyễn,et al.  Roles of vitamin D in amyotrophic lateral sclerosis: possible genetic and cellular signaling mechanisms , 2013, Molecular Brain.

[36]  J. Connor,et al.  Plasma biomarkers associated with ALS and their relationship to iron homeostasis , 2010, Muscle & nerve.

[37]  E. Novellino,et al.  New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function. , 2009, Journal of medicinal chemistry.

[38]  R. Batterham,et al.  The role of peptide YY in appetite regulation and obesity , 2009, The Journal of physiology.

[39]  I. Chiu,et al.  T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS , 2008, Proceedings of the National Academy of Sciences.

[40]  A. Grierson,et al.  Role of axonal transport in neurodegenerative diseases. , 2008, Annual review of neuroscience.

[41]  D. Larson,et al.  Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device , 2005, Perfusion.

[42]  M. McGrath,et al.  Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS) , 2005, Journal of Neuroimmunology.

[43]  D. Loskutoff,et al.  Monocyte chemoattractant protein 1 in obesity and insulin resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Wikkelsø,et al.  Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF , 1996, Journal of neurochemistry.

[45]  J. Coyle,et al.  Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis , 1990, Annals of neurology.

[46]  R. Bowser,et al.  Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis , 2016, Neurotherapeutics.

[47]  Y. Nakaya,et al.  Serum albumin levels correlate with inflammation rather than nutrition supply in burns patients: a retrospective study. , 2014, The journal of medical investigation : JMI.